New tools for coronary risk assessment - What are their advantages and limitations?

被引:160
作者
Pearson, TA [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Community & Prevent Med, Rochester, NY 14642 USA
关键词
risk factors; heart disease; prevention;
D O I
10.1161/hc0702.103727
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The concept of risk assessment and reduction, introduced initially by the Framingham Heart Study and refined in other models, forms the cornerstone of preventive cardiology. Risk factor assessment determines the therapeutic strategy, because the intensity of preventive intervention is tailored to the patient's risk of coronary heart disease. The conventional risk factors for coronary heart disease include elevated serum total cholesterol and LDL cholesterol, low HDL cholesterol, elevated blood pressure, cigarette smoking, diabetes, vascular disease, menopausal status (women only), and age. Aggressive risk factor reduction, formerly used exclusively in secondary prevention, may be pivotal to optimal patient management in high-risk primary prevention. A number of noninvasive imaging modalities have the potential to measure and to monitor atherosclerosis in asymptomatic individuals and include exercise ECG testing, electron beam computed tomography, magnetic resonance coronary angiography, positron emission tomography, ankle-brachial index, and B-mode ultrasound. Novel serum markers, including C-reactive protein and homocysteine, have the ability to gauge risk in the individual patient. Systemic therapy for risk reduction in primary prevention may be preferable to local therapy (eg, angioplasty and bypass) and may more effectively prevent acute coronary events than these more invasive approaches.
引用
收藏
页码:886 / 892
页数:7
相关论文
共 40 条
[1]   Predictive value of electron beam computed tomography of the coronary arteries - 19-month follow-up of 1173 asymptomatic subjects [J].
Arad, Y ;
Spadaro, LA ;
Goodman, K ;
LledoPerez, A ;
Sherman, S ;
Lerner, C ;
Guerci, AD .
CIRCULATION, 1996, 93 (11) :1951-1953
[2]   Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis [J].
Baller, D ;
Notohamiprodjo, G ;
Gleichmann, U ;
Holzinger, J ;
Weise, R ;
Lehmann, J .
CIRCULATION, 1999, 99 (22) :2871-2875
[3]  
Benitez RM, 2001, CLIN CARDIOL, V24, P642
[4]   VALUE OF MAXIMAL EXERCISE TESTS IN RISK ASSESSMENT OF PRIMARY CORONARY HEART-DISEASE EVENTS IN HEALTHY-MEN - 5 YEARS EXPERIENCE OF THE SEATTLE HEART WATCH STUDY [J].
BRUCE, RA ;
DEROUEN, TA ;
HOSSACK, KF .
AMERICAN JOURNAL OF CARDIOLOGY, 1980, 46 (03) :371-378
[5]   Effect of HMG-Coa reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography [J].
Callister, TQ ;
Raggi, P ;
Cooil, B ;
Lippolis, NJ ;
Russo, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (27) :1972-1978
[6]  
Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]  
Criqui M H, 1997, Vasc Med, V2, P221
[9]   Coronary calcium does not accurately predict near-term future coronary events in high-risk adults [J].
Detrano, RC ;
Wong, ND ;
Doherty, TM ;
Shavelle, RM ;
Tang, WY ;
Ginzton, LE ;
Budoff, MJ ;
Narahara, KA .
CIRCULATION, 1999, 99 (20) :2633-2638
[10]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622